# A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

> **NCT06024915** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** TQ05105 tablets
- **DRUG:** Itraconazole capsule
- **DRUG:** Rifampicin Capsule

## Key facts

- **NCT ID:** NCT06024915
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-21
- **Primary completion:** 2024-01-29
- **Final completion:** 2024-05-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06024915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06024915, "A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06024915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*